AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heber, D.
Right arrow Articles by Elashoff, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heber, D.
Right arrow Articles by Elashoff, R. M.
Agricola
Right arrow Articles by Heber, D.
Right arrow Articles by Elashoff, R. M.

American Journal of Clinical Nutrition, Vol 64, 472S-477S, Copyright © 1996 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Clinical detection of sarcopenic obesity by bioelectrical impedance analysis

D Heber, S Ingles, JM Ashley, MH Maxwell, RF Lyons and RM Elashoff
Department of Medicine, UCLA School of Medicine 90024-1742. DaveHeber@aol.com

To assess whether bioelectrical impedance analysis (BIA) provides clinically useful information on body composition beyond that obtained from measuring height and weight, we clinically classified 306 obese patients (233 females and 73 males) into tertiles of increasing fat- free mass estimated by BIA. Because fat-free mass by BIA is an estimate of lean body mass, the lowest tertile was clinically defined as sarcopenic obesity (reduced lean body mass), as contrasted with proportionate or muscular obesity in the next two tertiles. Fat mass in patients in each of the above tertiles based on BIA was then compared with fat mass estimated by using the equations of Garrow and Webster with body mass index (weight/height2). BIA-estimated fat mass was 4.3 kg greater in the sarcopenic group (n = 102) than predicted from body mass index. Fat mass predicted by BIA in the proportionate (n = 102) and muscular (n = 102) groups differed by less than the SEE of fat mass predicted by BMI. In premenopausal women at increased risk of breast cancer BIA showed a high prevalence of sarcopenic obesity (28/30) in these women at normal body mass indexes. Thus, BIA may be clinically useful for demonstrating sarcopenic obesity, but additional studies are needed to determine the metabolic and clinical significance of sarcopenic obesity.


This article has been cited by other articles:


Home page
 JCOHome page
C. L. Rock and W. Demark-Wahnefried
Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence
J. Clin. Oncol., August 1, 2002; 20(15): 3302 - 3316.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Demark-Wahnefried, B. L. Peterson, E. P. Winer, L. Marks, N. Aziz, P. K. Marcom, K. Blackwell, and B. K. Rimer
Changes in Weight, Body Composition, and Factors Influencing Energy Balance Among Premenopausal Breast Cancer Patients Receiving Adjuvant Chemotherapy
J. Clin. Oncol., May 1, 2001; 19(9): 2381 - 2389.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by The American Society for Nutrition